Vioxx, the implosion of Merck, and aftershocks at the FDA

@article{Horton2004VioxxTI,
  title={Vioxx, the implosion of Merck, and aftershocks at the FDA},
  author={Richard C. Horton},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={1995-1996}
}
  • R. Horton
  • Published 4 December 2004
  • Medicine
  • The Lancet
Disclosing research findings : determinants and impact of incomplete and partial scientific knowledge in the context of evidence-based medicine
THIS PAPER CONTRIBUTES TO THE CURRENT DEBATE ON THE RELIABILITY OF PUBLISHED RESEARCH. IN PARTICULAR, THIS STUDY FOCUSES ON THE SELECTIVE REPORTING OF RESEARCH FINDINGS IN CLINICAL TRIALS, DEFINED AS
Crime Opportunities Provided by Legislation in Market Sectors: Mobile Phones, Waste Disposal, Banking, Pharmaceuticals
Project Marc aims at developing a mechanism for assessing the risks of crime due to legislation and products in order to proof them against crime at EU level. Such a mechanism can only be developed
PHARMACOVIGILANCE: MORE THAN EVER, AN OVERALL RESPONSIBILITY FARMACOVIGILÂNCIA: CADA VEZ MAIS, UM DEVER DE TODOS
All medicines have side effects and, hence, should be followed up after they are introduced into the market. This is the simplest way to define and start talking about Pharmacovigilance. Another way
An Evidence-Hierarchical Decision Aid for Ranking in Evidence-Based Medicine
TLDR
A decision aid is introduced, HiDAD, which draws on the multi criteria decision making literature and implements the wide-spread intuition that there are different kinds of evidence with varying degrees of importance by relying on a strict ordinal ordering of kinds ofevidence.
Consequences of Disclosing Clinical Trial Results: Evidence from the Food and Drug Administration Amendments Act
We examine how the U.S. Food and Drug Administration Amendments Act (FDAAA) of 2007, which requires additional disclosures regarding clinical trial results, impacts information asymmetry between the
The production of ignorance
  • J. Launer
  • Political Science
    Postgraduate Medical Journal
  • 2020
TLDR
Anyone who is despondent about the assaults on truth in the recent parliamentary elections in the UK, or the last presidential contest in the United States, may find it salutary to read the comments of the great economist John Maynard Keynes on the British elections in 1931.
E-Synthesis: A Bayesian Framework for Causal Assessment in Pharmacosurveillance
TLDR
This article expands the Bayesian framework for evidence synthesis and adds “evidential modulators,” which bear on the assessment of the reliability of incoming study results, and applies the overall framework, “E-Synthesis”, to a case study.
The Changing Paradigm in Preclinical Toxicology: in vitro and in silico Methods in Liver Toxicity Evaluations
  • F. Noor
  • Biology
    Animal Experimentation: Working Towards a Paradigm Change
  • 2019
UNIVERSITI TEKNOLOGI MARA ANALYSIS OF ADVERSE DRUG REACTIONS RELATED TO DRUG-INDUCED RENAL INJURY BASED ON SPONTANEOUS ADVERSE DRUG REACTIONS REPORTING IN MALAYSIA
TLDR
Diclofenac was found to be the most reported drug causing renal injuries in Malaysia and can be considered as safe and effective therapeutic NSAIDs for the management of a variety acute and chronic condition, it has to be used with justifiable caution.
...
1
2
3
4
5
...

References

Failing the public health--rofecoxib, Merck, and the FDA.
  • E. Topol
  • Medicine, Political Science
    The New England journal of medicine
  • 2004
TLDR
On September 30, 2004, after more than 80 million patients had taken rofecoxib and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes.